Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study

Gunaldi M., Duman B. B., Afsar C. U., PAYDAŞ S., Erkisi M., KARA İ. O., ...More

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.22, no.2, pp.242-247, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.1177/1078155214567162
  • Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.242-247
  • Keywords: Trastuzumab, breast cancer, cardiotoxicity, onco-pharmacology, risk factors, ADJUVANT TRASTUZUMAB, CARDIAC DYSFUNCTION, THERAPY, DOXORUBICIN
  • Çukurova University Affiliated: Yes

Abstract

Background: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic.